Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Company Overview

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in molecular biology, genetics and drug discovery to address conditions with significant unmet medical needs.

Vertex is best known for its portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis by addressing defects in the CFTR protein. The company serves patients and healthcare providers in the United States and international markets through regulatory approvals and commercial operations across multiple regions.

Vertex also commercializes Casgevy, a gene-editing therapy developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia. In addition, the company markets Journavx, a non-opioid treatment for acute pain, and is advancing research programs in areas including type 1 diabetes, kidney disease and other serious conditions. Reshma Kewalramani has served as Vertex’s president and chief executive officer since 2017.

Key Stats

• Today's Range: $496.15 to $506.01
• 50-Day Range: $470.72 to $557.96
• 52-Week Range: $400.73 to $560.25
• Volume: 914,817 shs
• Average Volume: 970,242 shs
• Market Capitalization: $127.79 billion
• P/E Ratio: 29.31
• Dividend Yield: N/A
• Price Target: $575.13
• Consensus Rating: Moderate Buy

Vertex Pharmaceuticals Stock Analysis - MarketRank™

Vertex Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 108th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 20 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Vertex Pharmaceuticals has a consensus price target of $575.13, representing about 14.2% upside from its current price of $503.50.

Amount of Analyst Coverage

Vertex Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.01%

Earnings Growth

Earnings for Vertex Pharmaceuticals are expected to grow by 10.01% in the coming year, from $16.68 to $18.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vertex Pharmaceuticals is 29.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vertex Pharmaceuticals is 29.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.32.

Price to Earnings Growth Ratio

Vertex Pharmaceuticals has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Vertex Pharmaceuticals has a P/B Ratio of 6.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.86% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 5.03.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently increased by 1.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vertex Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vertex Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.84

News Sentiment

Vertex Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Vertex Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

36 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.

MarketBeat Follows

29 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 12% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vertex Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VRTX
• CIK: 875320
• Web: www.vrtx.com
• Phone: (617) 341-6100
• Fax: 617-576-2109
• Employees: 6,400
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vertex Pharmaceuticals: $575.13
• High Price Target: $665.00
• Low Price Target: $442.00
• Potential Upside/Downside: +14.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.96
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): $17.18
• Trailing P/E Ratio: 29.31
• Forward P/E Ratio: 30.19
• P/E Growth: 2.21
• Net Income: $3.95 billion
• Net Margins: 35.00%
• Pretax Margin: 41.90%
• Return on Equity: 23.09%
• Return on Assets: 16.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.19
• Quick Ratio: 2.74

Sales & Book Value

• Annual Sales: $12.00 billion
• Price / Sales: 10.65
• Cash Flow: $17.53 per share
• Price / Cash Flow: 28.72
• Book Value: $73.57 per share
• Price / Book: 6.84

Miscellaneous

• Outstanding Shares: 253,800,000
• Free Float: 253,297,000
• Market Cap: $127.79 billion
• Optionable: Optionable
• Beta: 0.28